Clinical trial
A Phase II Open-Label Multi-center Trial of Isotoxic Hypofractionated Chemoradiotherapy for NSCLC
NCT03606239 is registered in ClinicalTrials.gov with The Second Hospital of Hebei Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Open-Label Multi-center Trial of Isotoxic Hypofractionated Chemoradiotherapy for NSCLC
- Lead sponsor
- The Second Hospital of Hebei Medical University
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- February 1, 2019
- Completion date
- February 1, 2026
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.